Intellia Therapeutics (NASDAQ:NTLA) PT decreased to $64.00

Intellia Therapeutics (NASDAQ:NTLA – Get a Free Report) had its price target reduced by research analysts at Stifel Nicolaus from $80.00 to $64.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 209.63% from the company’s previous close.

Other research analysts have recently issued research reports on the stock. Truist Financial reissued a “buy” rating and issued a $120.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 24th. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. Royal Bank of Canada decreased their price target on Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.77, according to MarketBeat.com.

Get the latest report on NTLA

Intellia Therapeutics Stock Performance

NTLA opened at $20.67 on Wednesday. The company’s 50-day simple moving average is $23.43, and its 200-day simple moving average is $24.55. Intellia Therapeutics has a 52-week low of $19.21 and a 52-week high of $37.15. The firm has a market cap of $1.99 billion, a PE ratio of -3.86 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA – Get Your Free Report ) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. In the same quarter last year, the company posted EPS of ($1.40). The company’s quarterly revenue was down 48.5% year over year. On average, research analysts forecast that Intellia Therapeutics will post -5.19 earnings per share for the current year.

Hedge funds leverage Intellia Therapeutics

Hedge funds have recently added to or reduced their holdings in the stock. International Assets Investment Management LLC bought a new position in shares of Intellia Therapeutics in the fourth quarter valued at $715,000. Charles Schwab Investment Management Inc. raised its holdings in Intellia Therapeutics by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after buying an additional 18,987 shares during the period. BNP Paribas Financial Markets grew its position in shares of Intellia Therapeutics by 0.9% in the 4th quarter. BNP Paribas Financial Markets now owns 210,161 shares of the company’s stock valued at $6,408,000 after buying an additional 1,930 shares. in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Intellia Therapeutics by 5.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,170,829 shares of the company’s stock worth $35,704,000 after acquiring an additional 60,748 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Intellia Therapeutics by 23.3% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,204 shares of the company’s stock worth $242,000 after acquiring an additional 1,553 shares during the last quarter. Institutional investors own 88.77% of the company’s shares.

About Intellia Therapeutics

(Get a free report)

Intellia Therapeutics, Inc, a genome editing company, focuses on developing curative therapies. The company’s in vivo programs include NTLA-2001, which is in a Phase 1 clinical trial for the treatment of amyloidosis with transthyretin; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for lung disease associated with alpha-1 antitrypsin deficiency.

See Also

Get news and reviews for Intellia Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intellia Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.